HSIL has been shunned by investors so far because of the losses in its glass division. However, that business is on a turnaround and will turn profitable soon. The stock is on the verge of a re-rating and the time is opportune to buy it says Daljeet Kohli of IndiaNivesh
Daljeet Kohli has announced Kaveri Seed Co as his latest stock pick. Kaveri’s strong brand, high ROEs, high entry barriers, track record and exciting growth prospects have enticed Daljeet to put a buy on it. However, there are concerns regarding the stock
AIA Engineering reported strong operational results for Q4FY14 and the stock price has jumped 23% in a week (157% YOY). However, the entire euphoria is not reflected because AIA is an exporter and the strong rupee is causing anxiety. This situation gives an ideal opportunity for contrarians to accumulate the stock
The question as to what one should do about high quality Pharma and Info Tech stocks which are under-performing the Indices owing to the strength of the rupee is troubling investors. Dipen Sheth of HDFC Securities provides valuable guidance on the issue
Whirlpool’s MNC parentage, zero debt, powerful brands, marketing muscle and reasonable valuations have enticed Neha Majithia Of Microsec to put a “strong buy” on it but the question I am exploring is whether Bajaj Electricals offers better bang for the buck
S. P. Tulsian, the veteran trader-cum-investor knows better than anyone else the perils of investing in fundamentally weak stocks on the strength of speculative news. While Tulsian has got away lightly in the past, Spice Jet has proved to be his nemesis because it has done exactly the opposite of his predictions
Emkay has released a report pointing out that the rupee-led fears which have led to under-performance of Pharma stocks are overblown and that this is an opportunity for investors to buy high-quality stocks
R Sreesankar of Prabhudas Lilladhar has issued a research report stating that the Nifty is likely to head to 9000 in the next 18 to 24 months. He has recommended 12 top-quality mid-cap stocks and a few large-cap stocks for purchase
The appreciation in the value of the INR vis-à-vis the USD has caused Pharma & InfoTech stocks to under-perform the Index. Daljeet Kohli explains the extent of the impact and offers valuable advice on what investors should do
Axis Capital has conducted an in-depth review of 33 top-quality mid-cap stocks which are quoting at reasonable valuations and which have great potential
Recent Comments